|
⚲
|
| Keyboard |
| SV Health Investors LLC
✚
|
|
|---|---|
| CRD # | 160933 |
| SEC # | 801-110943 |
| CIK # | 0001587143 |
| AUM | 1,080.3 M (2026-03-31) |
| Employees | 26 (62% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-367-8100 |
| Address | 28 State Street Boston, MA 02109 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Bicycle Therapeutics PLC | 21.1 | ||
| Bioventus Inc | 10.4 | ||
| Arsanis Inc | 0.5 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | SV7 Plus Growth Fund LP | [2025-03-31] | 35.6 M | |
| Offered $60,000,000 · Filed 2024-11-05 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $60,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | SV TREX CoInvestment LP | 2025-03-31 | 8.0 M | |
| Other | SV7 Growth Fund Strategic Partners LP | [2023-03-30] | 15.5 M | |
| Filed 2022-04-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| VC | SV Life Sciences Fund IV CF LP | 2022-03-31 | 410.4 M | |
| VC | Medtech Convergence Fund LP | [2019-03-29] | 80.2 M | |
| Offered $94,000,000 · Filed 2019-03-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $94,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| Other | SV7 Growth Fund LP | [2019-03-29] | 91.3 M | 155.3 M |
| Offered $250,000,000 · Filed 2020-11-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining $158,690,177 · Duration More than one year · Revenue Not Applicable | ||||
| VC | DDF Parallel LLP | [2017-06-30] | 26.0 M | 19.3 M |
| Offered $302,381,000 · Filed 2017-10-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $276,413,669 · Duration More than one year · Revenue Not Applicable | ||||
| VC | SV Life Sciences Fund VI Strategic Partners LP | [2017-06-30] | 13.1 M | 8.7 M |
| Offered $13,130,000 · Filed 2017-04-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Not Applicable | ||||
| VC | SV Life Sciences Fund VI Strategic Partners LP | [2017-06-30] | 13.1 M | 13.3 M |
| Offered $13,130,000 · Filed 2017-04-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Dementia Discovery LP | [2016-03-30] | 26.0 M | 169.6 M |
| Offered $302,381,000 · Filed 2017-10-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $276,413,669 · Duration More than one year · Revenue Not Applicable | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 21 | 1.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 15 | 1.1 |
| By Discretionary | ||
| Discretionary | 15 | 1.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 15 | 1.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 1.1 | |
| Total | 15 | 1.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Michael Ross | Executive Officer | 88 | 5 | |
| James Garvey | Executive Officer | 42 | 4 | |
| Michael Balmuth | Executive Officer | 19 | 3 | |
| Kate Bingham | Executive Officer | 8 | 3 | |
| Paul Laviolette | Executive Officer | 59 | 2 | |
| David Milne | Executive Officer | 40 | 2 | |
| Thomas Flynn | Executive Officer | 34 | 2 | |
| Aaron Sandoski | Executive Officer | 21 | 2 | |
| Eugene Hill | Executive Officer | 20 | 2 | |
| Lutz Giebel | Executive Officer | 19 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001587143] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Comparable Firms | State | AUM |
|---|---|---|
|
NexPoint Real Estate Advisors X LP
✚
|
TX | 1,098.2 M |
|
Asset Consulting Group LLC
✚
|
MO | 1,096.1 M |
|
CS Capital Management Inc
✚
|
CA | 1,090.3 M |
|
Riot Ventures Management LLC
✚
|
CA | 1,086.1 M |
|
CIM Capital IC Management LLC
✚
|
CA | 1,080.5 M |
|
Power Sustainable Manager US Inc
✚
|
FL | 1,072.6 M |
|
Counterpointe Investment Management LLC
✚
|
CT | 1,067.7 M |
|
Twin Oak ETF Company
✚
|
MA | 1,057.8 M |
|
Nordea Investment Management North America Inc
✚
|
NY | 1,054.5 M |
|
Virtus Alternative Investment Advisers LLC
✚
|
CT | 1,053.0 M |